Waldenstrom Macroglobulinemia Clinical Trials

237 clinical trials for Waldenstrom Macroglobulinemia across international registries, including 30 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas — RECRUITING · PHASE1
• Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia — RECRUITING
• A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies — RECRUITING · PHASE1
• A Long-term Extension Study of PCI-32765 (Ibrutinib) — RECRUITING · PHASE3
• Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) — RECRUITING
• A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies — RECRUITING · PHASE1
• Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma — RECRUITING · PHASE2
• A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) — RECRUITING · PHASE1
• A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies — RECRUITING · PHASE1
• Combating Cancer-Related Fatigue: A Personalized Supportive Care Program — RECRUITING · NA
• A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) — RECRUITING · PHASE2
• Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM — RECRUITING · PHASE2
• Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome — RECRUITING
• Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia — RECRUITING · PHASE2
• Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma — RECRUITING · PHASE1
• Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader — RECRUITING · PHASE1
• SynKIR-310 for Relapsed/Refractory B-NHL — RECRUITING · PHASE1
• A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies — RECRUITING · PHASE1
• Epcoritamab in Previously Treated WM — RECRUITING · PHASE2
• Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study — RECRUITING
• Spanish Registry of Patients With IgM Monoclonal Gammopathies — RECRUITING
• Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. — RECRUITING · PHASE1
• Study of SGR-1505 in Mature B-Cell Neoplasms — RECRUITING · PHASE1
• AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia — RECRUITING · PHASE2
• Watch and Wait or Worry and Wait in Indolent Lymphoma — RECRUITING
• Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia — RECRUITING · NA
• Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia — RECRUITING · NA
• Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM — RECRUITING · PHASE2
• Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia — RECRUITING · PHASE2
• Evaluation of Iopofosine I 131 vs. R-CD in WM Patients — NOT_YET_RECRUITING · PHASE3
• Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer — ACTIVE_NOT_RECRUITING
• Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) — ACTIVE_NOT_RECRUITING · PHASE2
• An Open-label, Phase 2 Study of ACP-196 in Subjects with Waldenström Macroglobulinemia — TERMINATED · PHASE2
• Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy — NOT_YET_RECRUITING
• Study of Oral LOXO-338 in Patients With Advanced Blood Cancers — COMPLETED · PHASE1
• Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas — COMPLETED · PHASE2
• An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia — ACTIVE_NOT_RECRUITING · PHASE2
• A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) — ACTIVE_NOT_RECRUITING · PHASE1
• Preliminary Assessment of [18F]BL40 in PET/CT Scans — COMPLETED
• Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia — ACTIVE_NOT_RECRUITING · PHASE2
• Rifaximin in Patients With Monoclonal Gammopathy — COMPLETED · PHASE1
• Loncastuximab Tesirine in WM — ACTIVE_NOT_RECRUITING · PHASE2
• ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies — COMPLETED · PHASE1
• Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia — ACTIVE_NOT_RECRUITING · PHASE2
• Ibrutinib + Venetoclax in Untreated WM — ACTIVE_NOT_RECRUITING · PHASE2
• Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia — TERMINATED · PHASE2

Refine this search